Table 1.
Clinical characteristics of the patients from the Leucegene cohort, with the PRMT2low and PRMT2high groups
| Leucegene | PRMT2low | PRMT2high | Statistical significance | |
|---|---|---|---|---|
| (n = 371) | (n = 37) | (n = 37) | ||
| De novo | 346 (93.3%) | 36 (97.3%) | 35 (94.6%) | |
| t-AML | 25 (6.7%) | 1 (2.7%) | 2 (5.4%) | |
| Sex | ||||
| Male | 210 (56.6%) | 19 (51.4%) | 23 (62.2%) | |
| Female | 161 (43.4%) | 18 (48.6%) | 14 (37.8%) | |
| Age (years) | ||||
| Median | 58 | 57 | 55 | |
| Range | 17-87 | 22-82 | 18-84 | |
| WBC count (x109/L) | ||||
| Median | 33.2 | 14.5 | 73.4 | *** |
| Range | 0.8-361.2 | 1.3-322.5 | 2.9-361.2 | |
| Cytogenetic risk | ||||
| Favorable | 46 (12.4%) | 4 (10.8%) | 9 (24.3%) | |
| Intermediate | 206 (55.5%) | 19 (51.4%) | 22 (59.5%) | |
| Adverse | 117 (31.5%) | 14 (37.8%) | 6 (16.2%) | |
| FAB subtype | ||||
| M0 | 23 (6.2%) | 2 (5.4%) | 4 (10.8%) | |
| M1 | 103 (27.8%) | 10 (27.0%) | 14 (37.8%) | |
| M2 | 50 (13.5%) | 9 (24.3%) | 7 (18.9%) | |
| M4 | 56 (15.1%) | 4 (10.8%) | 4 (10.8%) | |
| M5 | 63 (17%) | 5 (13.5%) | 5 (13.5%) | |
| M6 | 8 (2.2%) | 1 (2.7%) | 0 | |
| M7 | 2 (0.5%) | 0 | 0 | |
| Not classificable | 66 (17.8%) | 6 (16.2%) | 3 (8.1%) |
WBC white blood count.